Doctors at a cancer conference in Seoul just shared news that could change the future for people facing one of the toughest forms of lung cancer. In a large clinical trial, an experimental drug called gotistobart helped patients live for a median of 18.5 months — compared with just 10 months for patients on the standard treatment docetaxel. That is nearly double the survival time, and it was enough to cut a patient's risk of dying by 43% over the course of the study.
The findings come from stage 1 of a trial called PRESERVE-003, presented at the 2026 World Conference on Lung Cancer in Seoul, Republic of Korea. The patients involved had metastatic squamous non-small cell lung cancer — a specific, aggressive type of lung cancer that has spread beyond the lungs. All of them had already been treated with a class of drugs called PD-(L)1 inhibitors and had seen their disease come back. That matters, because when these frontline treatments stop working, patients have far fewer options left.
Gotistobart is an "anti-CTLA-4" antibody, a lab-made protein that helps the body's own immune system fight the tumor. Specifically, it works by depleting regulatory T cells inside the tumor's environment — the cells that usually put the brakes on the immune system and let cancer hide. Removing those brakes lets immune cells attack more effectively. In this trial, patients who got higher doses of the drug tended to survive longer, which supports the dosing plan being used.
The drug also appears to reach higher levels in the body than a similar older drug called ipilimumab, which suggests it might work more efficiently. The researchers reported the safety profile matched earlier studies, with no new or unexpected problems.
"These updated survival findings reinforce the potential of gotistobart to provide a meaningful new treatment option for patients with metastatic squamous NSCLC whose disease has progressed following PD-(L)1 therapy," said Dr. Rama Balaraman of Ocala Oncology Center in Florida, who presented the study.
The trial is not finished. These promising results are pushing the research forward into the pivotal second stage of PRESERVE-003, where the drug will be tested in a larger group of patients. If those results hold up, gotistobart could become a new standard of care for people who have run out of other options. For a disease that affects millions worldwide, that would be a genuinely hopeful step — one measured in extra months of life that matter enormously to the people living them and their families.